CXCR1
C-X-C chemokine receptor type 1
As of the edition of 20 October 2026, CXCR1 (C-X-C chemokine receptor type 1, UniProt P25024) has 4 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25024
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Cancer; Hormones; Immune system; Lungs and airways; Nutrition and metabolism; Skin and connective tissue; Digestive system; Blood and lymph
- Registered trials of its drugs
- 38
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 3 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Reparixin | Stopped | Phase 3 | none listed |
| SX-682 | Active | Phase 2 | none listed |
| Ladarixin | Stopped | Phase 2 | none listed |
| DF2755A | Stopped | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Dompé Farmaceutici | Route A |
The other 1 company at CXCR1
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at CXCR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.